- 1. Zoledronic Acid
- [A synthetic imidazole bisphosphonate analog of pyrophosphate with bone-resorption-inhibiting activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This drug also inhibits farnesyl pyrophosphate (diphosphate) synthase, thereby preventing protein prenylation within the mevalonate pathway. This leads to the loss of downstream metabolites essential for osteoclast function, leading to the induction of apoptosis and eventually, osteoclast-cell death. Zoledronic acid's inhibitory effects on osteoclast-mediated bone resorption result in decreased bone turnover and stabilization of the bone matrix, two effects that contribute to the analgesic properties associated with painful osteoblastic lesions. The drug also reduces serum calcium concentrations associated with hypercalcemia. ( NCI )] (UMLS (NCI) C0257685) =Organophosphorus Compound; Pharmacologic Substance =ZOLEDRONIC;
Unclassified Ingredients =ZOLEDRONIC ACID 4 MG | - 4. ZOLPIDEM
- (UMLS (NCI) C0078839) =Organic Chemical; Pharmacologic Substance =pyridine;
[CN309] SEDATIVES/HYPNOTICS, OTHER =Zolpidem Tartrate |
- 2. ZOLIMIDINE
- (UMLS (NCI) C0650163) =Organic Chemical; Pharmacologic Substance ;
| - 5. Zolpidem Tartrate
- [The tartrate salt form of zolpidem, an imidazopyridine derivative with sedative-hypnotic property. Zolpidem, a non-benzodiazepine compound, selectively binds to the omega-1 subclass of the gamma-aminobutyric acid (GABA) type A receptor, a chloride ionophore complex in the brain. This leads to the opening of chloride channels causing hyperpolarization and inhibition of neuronal firing, and mimicking synaptic actions of GABA. ( NCI )] (UMLS (NCI) C0724725) ZOLPIDEM TARTRATE PREPARATION =Organic Chemical; Pharmacologic Substance ;
=ZOLPIDEM;
=ZOLPIDEM TARTRATE 5 MG;
ZOLPIDEM TARTRATE 10 MG;
|
home
